Kristin Sokol, MD
Allergy & Immunology · Rockville, MDNPI 1982903498
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Sanofi at 34.2% of the total. Among allergy & immunology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $132.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$21K
- Novartis$11K
- Regeneron Healthcare Solutions, Inc.$7K
- Regeneron$6K
- Genentech USA, Inc.$5K
- Pfizer$3K
- plus $9K from 25 others
What the payments were for
- Consulting fees$30,05148%
- Speaking & faculty fees$14,71124%
- Grants$3,5736%
- Travel & lodging$2,3414%
- Food & beverage$11,03618%
- Education$3571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 58 | $21,222 |
| Novartis | 35 | $11,339 |
| Regeneron Healthcare Solutions, Inc. | 60 | $6,529 |
| Regeneron | 4 | $5,682 |
| Genentech USA, Inc. | 19 | $4,888 |
| Pfizer | 19 | $2,940 |
| Aquestive Therapeutics, Inc. | 2 | $1,869 |
| Kaleo, Inc. | 14 | $1,784 |
| AstraZeneca | 67 | $1,458 |
| GSK | 57 | $1,198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $715 |
| Amgen | 25 | $499 |
| Grifols USA, LLC | 16 | $391 |
| Incyte Corporation | 11 | $334 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $222 |
| Biocryst US Sales Co., LLC | 8 | $185 |
| Alk-abello, Inc | 7 | $148 |
| CSL Behring | 6 | $147 |
| Pharming Healthcare, Inc. | 4 | $112 |
| Phadia US Inc. | 4 | $65 |
| Ionis Pharmaceuticals, Inc. | 2 | $55 |
| Optinose US, Inc. | 2 | $48 |
| LEO Pharma Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| ADMA Biomanufacturing LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Covis Pharma GmbH | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,069 in reported general payments places this provider in the 90th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 11 | $40,916 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Rockville
- Sudhir SekhsariaRockville$87K
- Rachel SchreiberRockville$48K
- Julia SohnRockville$16K
- Nneoma ObiejembaRockville$11K
- Paul KeiserRockville$7K
- Jordana GoldmanRockville$6K
- Gina Dapul-HidalgoRockville$5K
- Ryan BolotteRockville$4K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.